Alnylam Pharmaceuticals Q2 Adjusted EPS $(1.62) Beats $(1.72) Estimate, Sales $318.75M Miss $331.73M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported Q2 adjusted EPS of $(1.62), beating the estimate of $(1.72) by 5.81%. However, the company's sales of $318.75M missed the estimate of $331.73M by 3.91%. This represents a 20.2% increase in EPS and a 41.78% increase in sales compared to the same period last year.
August 04, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals reported better than expected Q2 EPS but missed on sales. This could have a mixed impact on the stock.
Alnylam Pharmaceuticals reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which could be a concern. These mixed results could lead to a neutral impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100